Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H37ClN |
| Molecular Weight | 338.978 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 1 |
SHOW SMILES / InChI
SMILES
CCCCCCC[N+](CC)(CC)CCCCC1=CC=C(Cl)C=C1
InChI
InChIKey=WPSYTTKBGAZSCX-UHFFFAOYSA-N
InChI=1S/C21H37ClN/c1-4-7-8-9-11-18-23(5-2,6-3)19-12-10-13-20-14-16-21(22)17-15-20/h14-17H,4-13,18-19H2,1-3H3/q+1
| Molecular Formula | C21H37ClN |
| Molecular Weight | 338.978 |
| Charge | 1 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Clofilium is a quaternary ammonium compound that acts as potassium channel blocker. Clofilium is a class III agent. Clofilium increases atrial and ventricular effective refractory period without changing conduction time and, despite no apparent change in premature ventricular complex frequency, it can abolish the ability to induce ventricular tachycardia by programmed stimulation and is also well tolerated.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 2.0 nM [IC50] | |||
Target ID: Q5JUK3 Gene ID: 57582.0 Gene Symbol: KCNT1 Target Organism: Homo sapiens (Human) |
|||
Target ID: O95259 Gene ID: 3756.0 Gene Symbol: KCNH1 Target Organism: Homo sapiens (Human) |
255.0 nM [IC50] | ||
| 840.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator​
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| yes [Inhibition 20 uM] | ||||
| yes [Inhibition 20 uM] |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Humans: Clofilium was administered as a single bolus intravenously in doses ranging from 60 to 300 ug/kg during electrophysiologic testing. https://www.ncbi.nlm.nih.gov/pubmed/6881021
Eight dogs were given clofilium phosphate (0.34 mg/kg, iv). The maximum clofilium effect was a 31% decrease in threshold current and a 54% decrease in threshold energy.
Route of Administration:
Intravenous
In Vitro Use Guide
Curator's Comment: Clofilium (0.1-100 umol/l) inhibited high voltage-activated Ca2+ currents in concentration- and use-dependent manners. Clofilium acted as a potent antagonist of NMDA receptor channels, preferably blocked the NMDA steady-state current at a low concentration (0.1 umol/l). At concentrations of >100 umol/l, clofilium blocked both peak and steady-state NMDA currents in a voltage-independent manner. Clofilium also inhibited the Na+, K+-ATPase current with an IC50 of 7.5 umol/l. https://www.ncbi.nlm.nih.gov/pubmed/15637453
Clofilium at < or = 10(-6) M had no effect on WKY portal vein contractions and at < or = 3 x 10(-4) M had no effect on WKY or SHR quiescent mesenteric and intralobar pulmonary arteries. 3. Clofilium at 10(7) - 10(-5) M prolonged the WKY left ventricular action potentials and with 10(-6) and 10(-5)M this included after-depolarizations. 4. Clofilium at < or = 3 x 10(-5) M augmented the peak force, prolonged the contractions and did not cause arrhythmias in the absence and presence of isoprenaline on left ventricle strips from 12-month-old WKY.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:29:26 GMT 2023
by
admin
on
Fri Dec 15 15:29:26 GMT 2023
|
| Record UNII |
847G178BMC
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C47793
Created by
admin on Fri Dec 15 15:29:26 GMT 2023 , Edited by admin on Fri Dec 15 15:29:26 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C022799
Created by
admin on Fri Dec 15 15:29:26 GMT 2023 , Edited by admin on Fri Dec 15 15:29:26 GMT 2023
|
PRIMARY | |||
|
C83631
Created by
admin on Fri Dec 15 15:29:26 GMT 2023 , Edited by admin on Fri Dec 15 15:29:26 GMT 2023
|
PRIMARY | |||
|
CLOFILIUM
Created by
admin on Fri Dec 15 15:29:26 GMT 2023 , Edited by admin on Fri Dec 15 15:29:26 GMT 2023
|
PRIMARY | |||
|
68379-02-2
Created by
admin on Fri Dec 15 15:29:26 GMT 2023 , Edited by admin on Fri Dec 15 15:29:26 GMT 2023
|
PRIMARY | |||
|
2798
Created by
admin on Fri Dec 15 15:29:26 GMT 2023 , Edited by admin on Fri Dec 15 15:29:26 GMT 2023
|
PRIMARY | |||
|
847G178BMC
Created by
admin on Fri Dec 15 15:29:26 GMT 2023 , Edited by admin on Fri Dec 15 15:29:26 GMT 2023
|
PRIMARY | |||
|
DTXSID9048568
Created by
admin on Fri Dec 15 15:29:26 GMT 2023 , Edited by admin on Fri Dec 15 15:29:26 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
